摘要
目的研究慢性阻塞性肺疾病急性加重期应用孟鲁司特钠与多索茶碱治疗的效果。方法随机抽取2014年1月—2016年12月该院收治的230例慢性阻塞性肺疾病急性加重期患者作为研究对象,根据随机数字法,将230例患者分成两组,其中115例患者应用多索茶碱治疗设作对照组,另外115例患者在对照组治疗基础上增加孟鲁司特钠治疗设作观察组,对比两组治疗效果和治疗前后肺功能改善情况、治疗后不良反应。结果观察组治疗总有效率95.65%,对照组治疗总有效率82.61%,与对照组相比观察组疗效更为理想,两组对比差异有统计学意义(P<0.05);治疗前,观察组FEV1(1.32±1.69)L,FEV1/FV(45.25±6.10)%;对照组FEV1(1.32±1.70)L,FEV1/FV(45.26±6.11)%;两组患者肺功能对比差异无统计学意义(P>0.05);治疗后,观察组FEV1(2.35±1.95)L,FEV1/FV(71.65±7.19)%;对照组FEV1(1.87±1.70)L,FEV1/FV(62.35±5.66)%;两组患者肺功能对比差异无统计学意义(P>0.05);两组患者肺功能改善情况均优于治疗前,观察组肺功能指标改善情况优于对照组,两组对比差异有统计学意义(P<0.05);观察组用药期不良反应发生率13.91%;对照组用药期间不良反应发生率11.30%,两组患者治疗后不良反应对比差异无统计学意义(P>0.05)。结论慢性阻塞性肺疾病急性加重期应用孟鲁司特钠与多索茶碱治疗效果理想,未见明显不良反应,值得推广应用。
Objective To research the application effect of montelukast and doxofylline in treatment of chronic obstructive pulmonary disease during the acute exacerbation stage. Methods 230 cases of patients with chronic obstructive pulmonary disease during the acute exacerbation stage admitted and treated in our hospital from January 2014 to December 2016 were selected as the research objects and divided into two groups with 115 cases in each, the control group were treated with doxofylline, while the observation group were treated with montelukast and doxofylline, and the treatment effect, lung function improvement condition and adverse reactions after treatment were compared between the two groups. Results The total treatment effective rate was 95.65% in the observation group and 82.61% in the control group, and the curative effect in the control group was more ideal, and the difference between the two groups had statistical significance（P〈0.05）, before treatment, the differences in the FEV1 and FEV1/FV between the observation group and the control group had no statistical significance [（1.32 ±1.69）L,（45.25 ±6.10）% vs（1.32 ±1.70）L,（45.26 ±6.11）% ], after treatment, the differences in the FEV1 and FEV1/FV between the observation group and the control group had no statistical significance, [（2.35±1.95）L,（71.65±7.19）% vs（1.87±1.70）L,（62.35±5.66）%], and the lung function index improvement in the observation group was better than that in the control group, and the difference had statistical significance（P〈0.05）, and the difference in the incidence rate of adverse reactions between the observation group and the control group had no statistical significance（13.91% vs11.30%）. Conclusion The effect of montelukast and doxofylline in treatment of chronic obstructive pulmonary disease during the acute exacerbation stage is ideal without obvious adverse reactions, which is worth promotion and application.
出处
《中外医疗》
2017年第6期127-129,共3页
China & Foreign Medical Treatment
关键词
慢性阻塞性肺疾病
急性加重期
孟鲁司特钠
多索茶碱
Chronic obstructive pulmonary disease
Acute exacerbation stage
Montelukast
Doxofylline
